About the job
About Arc Institute
Arc Institute is a pioneering independent nonprofit research organization situated at the intersection of artificial intelligence and biology. Our mission is to expedite scientific advancements and unravel the complexities behind various diseases. Established in 2021 and located in Palo Alto, we collaborate closely with renowned institutions such as Stanford University, UC Berkeley, and UC San Francisco.
Our unique model allows scientists the liberty to engage in extensive research without the constraints of commercial pressures, supported by long-term funding and resources akin to industry standards. Our Technology Centers and Core Investigator labs synergize to tackle challenges that neither could address independently.
Our two key initiatives exemplify our innovative approach:
- Virtual Cell Initiative: Constructing a comprehensive virtual cell model to uncover disease mechanisms and propose drug targets, thereby accelerating the transition from biological insights to clinical trials.
- Alzheimer's Disease Initiative: Investigating the genes, pathways, and environmental influences linked to Alzheimer’s disease to create drug candidates that address its fundamental causes.
With over 300 dedicated researchers at our Palo Alto headquarters, we are backed by significant long-term philanthropic support.
About the Position
The Hsu Lab and Konermann Lab are inviting applications for a Scientist specializing in Nucleic Acid Biochemistry. This role focuses on the mechanistic exploration and engineering of Bridge Recombinases, naturally occurring RNA-guided DNA recombinases that we have recently identified and demonstrated to programmably insert, excise, and invert DNA (Nature, 2024; Science, 2025). The successful candidate will lead the next phase of the evolution of Bridge Recombinases, building on our foundational work with IS110 and ISCro4 as programmable tools. You will collaborate with an interdisciplinary team aimed at engineering bridge RNAs and recombinases for extensive genome modifications, therapeutic gene circuit integration, and seamless disease correction.
